Price (delayed)
$1.4
Market cap
$42.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$40.69M
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly
There are no recent dividends present for DYAI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.